128 related articles for article (PubMed ID: 10211093)
1. Antitumour activity of oxaliplatin in neuroblastoma cell lines.
Riccardi A; Ferlini C; Meco D; Mastrangelo R; Scambia G; Riccardi R
Eur J Cancer; 1999 Jan; 35(1):86-90. PubMed ID: 10211093
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma.
Riccardi A; Meco D; Ferlini C; Servidei T; Carelli G; Segni G; Manzotti C; Riccardi R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):498-504. PubMed ID: 11459202
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
4. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.
Servidei T; Ferlini C; Riccardi A; Meco D; Scambia G; Segni G; Manzotti C; Riccardi R
Eur J Cancer; 2001 May; 37(7):930-8. PubMed ID: 11313183
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.
Donzelli E; Carfì M; Miloso M; Strada A; Galbiati S; Bayssas M; Griffon-Etienne G; Cavaletti G; Petruccioli MG; Tredici G
J Neurooncol; 2004; 67(1-2):65-73. PubMed ID: 15072449
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
Mohammed MQ; Retsas S
Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
[TBL] [Abstract][Full Text] [Related]
7. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):109-14. PubMed ID: 9220289
[TBL] [Abstract][Full Text] [Related]
8. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin activity in head and neck cancer cell lines.
Espinosa M; Martinez M; Aguilar JL; Mota A; De la Garza JG; Maldonado V; Meléndez-Zajgla J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):301-5. PubMed ID: 15619139
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin in ovarian cancer.
Sessa C; ten Bokkel Huinink WW; du Bois A
Ann Oncol; 1999; 10 Suppl 1():55-7. PubMed ID: 10219454
[TBL] [Abstract][Full Text] [Related]
11. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells.
Rave-Fränk M; Schmidberger H; Christiansen H; Boll C; Lehmann J; Weiss E
Int J Radiat Biol; 2007 Jan; 83(1):41-7. PubMed ID: 17357438
[TBL] [Abstract][Full Text] [Related]
14. p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.
Petit T; Bearss DJ; Troyer DA; Munoz RM; Windle JJ
Mol Cancer Ther; 2003 Feb; 2(2):165-71. PubMed ID: 12589033
[TBL] [Abstract][Full Text] [Related]
15. The mitochondrial apoptotic pathway is induced by Cu(II) antineoplastic compounds (Casiopeínas
García-Ramos JC; Gutiérrez AG; Vázquez-Aguirre A; Toledano-Magaña Y; Alonso-Sáenz AL; Gómez-Vidales V; Flores-Alamo M; Mejía C; Ruiz-Azuara L
Biometals; 2017 Feb; 30(1):43-58. PubMed ID: 27988860
[TBL] [Abstract][Full Text] [Related]
16. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
Arnould S; Hennebelle I; Canal P; Bugat R; Guichard S
Eur J Cancer; 2003 Jan; 39(1):112-9. PubMed ID: 12504667
[TBL] [Abstract][Full Text] [Related]
17. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
18. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
19. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.
Voland C; Bord A; Péleraux A; Pénarier G; Carrière D; Galiègue S; Cvitkovic E; Jbilo O; Casellas P
Mol Cancer Ther; 2006 Sep; 5(9):2149-57. PubMed ID: 16985047
[TBL] [Abstract][Full Text] [Related]
20. Chlorogenic Acid Interaction with Cisplatin and Oxaliplatin: Studies in Cervical Carcinoma Cells.
Catanzaro D; Filippini R; Vianello C; Carrara M; Ragazzi E; Montopoli M
Nat Prod Commun; 2016 Apr; 11(4):499-502. PubMed ID: 27396204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
